Goodbye or arrivederci?
Our new vocabulary gene, genome, molecular, targeted, personalised no longer inspires the confidence it once did, and as the cancer community prepares to gather at the 18th ECCO – 40th ESMO European Cancer [more]
collaboration
Denis Lacombe quietly orchestrating the clinical research revolution
The scientific complexity and economic cost of developing new cancer therapies demand a level of collaboration and sharing that takes both industry and academia well beyond their comfort zones. EORTC head Denis Lacombe believes he [more]
Cancer Core Europe
Can deep and close-knit collaboration between a handful of elite centres achieve what broader European research platforms and projects cannot? There has been talk about setting up a European cancer institute to rival the American [more]
Change must come from within
Is progress against cancer is being stifled because young researchers are obliged to spend their best years competing for grants within a system biased against innovation? Half a century ago, a man named Denis Burkitt [more]
Enriqueta Felip: breaking boundaries in lung cancer
Building a lung cancer team that works seamlessly to do the best for each patient was the biggest challenge in Enriqueta Felips career. Her focus today is on increasing collaboration across Europe, which she sees [more]
What did we learn from the European Partnership for Action Against Cancer?
The recently concluded Partnership programme marked the first time that EU member states have taken a joint approach to improving cancer plans and the organisation of services. Was it a worthwhile exercise? And where do [more]
How Europe can develop better, cheaper cancer drugs
Modern tools of biological investigation give us opportunities to develop drugs much more efficiently. The president of Europes most important trials organisation explains how these opportunities can and must be exploited to start [more]